For personal use only

Transcription

1 // 1 INSPIRING THE WORLD TO MOVE WELL INVESTOR UPDATE JANUARY 2017

2 DISCLAIMER // 2 This presentation does not constitute investment, legal, taxation or other advice and the presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusions on such matters and should make your own independent assessment of the information presented. No responsibility is accepted by dorsavi or any of its respective officers, employees, agents, advisers or associates for any of the information or for any action taken by you on the basis of that information. Any and all use of the information is at your own risk. Certain information may relate to protected intellectual property rights owned by dorsavi Ltd (the "Company ). Except as required by law, no representation or warranty, express or implied, is made as to the accuracy, completeness or correctness of the information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this information and to the extent permitted by law, you release dorsavi and its respective officers, employees, agents, advisers and associates from any liability (including, without limitation, indirect or consequential loss or damage, or loss or damage arising by negligence) arising as a result of the reliance by you or any other person on anything contained in or omitted from this document or presentation.

3 For personal use only // 3 AGENDA About dorsavi Operational update ViSafe overview ViMove overview ViPerform overview Outlook INSPIRING THE WORLD TO MOVE WELL REVOLUTIONARY WEARABLE SENSOR TECHNOLOGY

4 // 4 About dorsavi

5 // 5

6 BOARD AND SENIOR MANAGEMENT // 6 Chairman Herb Elliott Non Executive Director Greg Tweedly Non Executive Director Michael Panaccio Non Executive Director Ash Attia Director & CEO Andrew Ronchi CFO Damian Connellan CIO Meagan Blackburn CPO Muhammad Umer CMO Megan Connell Head of Sales and Operations Australia Matt May Head of Sales and Operations Europe Zoë Whyatt Head of Sales and Operations US Mark Heaysman

7 OUR BUSINESS: SOLID FOUNDATION FOR GROWTH // 7 Three key business divisions with diversified revenue streams Organisational health and safety Clinical Elite sports Market leader with first mover advantage Patent protected technology Significant barriers to entry and limited competition FDA approval TGA approval CE Mark Currently focused on three key geographies United States United Kingdom Australia

8 THE HARDWARE AND PRODUCTS // 8 Patent protected movement algorithms on medical-grade sensor technology Function-specific applications which deliver meaningful movement data to our target markets OHS solution to determine, measure and mitigate high risk activities Significant appetite for innovative manual handling solutions Executive and board-level focus on reducing injuries and associated costs Budget readily available Clinical solution with turnkey applications for low back, running and a range of other functional measures Early adopter advocates in key geographic markets of Australia, USA and UK Distribution partners in USA and UK Elite sporting solution used in off-field environments to measure stress and prevent injury Widespread use across many codes AFL, NRL, NBA, NFL Sporting business growing via word of mouth

9 For personal use only // 9?

10 // 10 Operational Update

11 FINANCIAL OVERVIEW // 11 For personal use only 3,000 dorsavi Customer Revenue H Revenue 398, ,380 1,358,218 3,019,000 1,730,000* 2,500 2,000 1,008 EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A Loss from continuing operations (1,659,235) (3,562,024) (8,036,161) (5,237,102) N/A Cash position $13.97M $5.74M $6.04M $8.90M $ Thousand 1, Q4 Q3 Q2 dorsavi Ltd (ASX : DVL) *unaudited results 1, Q1 Share price $0.49 Shares on issue 167,305, Market capitalisation $82M FY13 FY14 FY15 FY16 FY17

12 STRONG GLOBAL GROWTH // 12 dorsavi Sales Revenue $2.0M $1.8M $1.6M $1.4M $1.2M $1.0M $0.8M $0.6M Q4 Q3 Q2 Q1 $0.4M $0.2M $0.0M FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 AU UK US

13 BUSINESS MATURING: IMPROVING KEY BUSINESS METRICS // 13 Sales Revenue (AUD) Total Expenses excl. COGS (AUD) Operating Loss before tax (AUD) 2,000 1,800 1,600 1,400 $1,292,000 $1,729,000* 725 4,500 4,000 3,500 3,000 $4,147,000 2,036 $3,253,000** $3.3m 1,200 1, Q2 Q1 2,500 2,000 1, Q2 Q $1.7m* ,000 2, H1 - FY16 H1 - FY17 0 H1 - FY16 H1 - FY17 0 H1 - FY16 H1 - FY17 ** Subject to change pending audit review and FX revaluation * Pending audit review including foreign currency translation reserve reversal * Pending audit review

14 EXECUTION ACROSS THE PRODUCT LINES // 14 ViSafe (OHS) ViSafe continues to grow across all three geographic markets Launched myvisafe - new ViSafe solution which will generate annuity revenue Three myvisafe customers signed in December ViMove (Clinical) Beachhead Clients UK: YourPhysioPlan (distributor of ViMove and ViPerform into UK physio market) US: Select Medical (2,000 clinical sites) Initial pilot of 20 sites Clinical trial publication using ViMove shows 45% reduction in chronic low back pain & 73% improvement in function Health economic paper released which shows ViMove delivers both improved clinical outcomes and reduced economic impact an unusually good result ViPerform (Sport) NBA Teams (LA Lakers) NFL Teams (New England Patriots) Initial US College sites (Ohio State & Marquette) Launched Athletic Movement Index to screen school/college aged students screening 800 in first three months

15 // 15 REDUCING COSTS & INJURY IMPROVING PRODUCTIVITY BUILDING SAFETY CULTURE INSPIRING THE WORLD TO MOVE WELL

16 // 16

17 SCALABLE REVENUE MODEL // 17 $40,000 Risk Assessment $100,000 Solution $300,000 Implementation Long Term Annuity Monitor Workforce

18 ANNUITY REVENUE INTRODUCED // 18 Launched in December 2016 Three customers signed up Self-managed solution with ongoing revenue stream Complementary to other ViSafe offerings

19 LAUNCHED AGENT MODEL FOR RAPID REVENUE GROWTH // 19 Scalable model: Direct sales representatives in key markets Sales partnerships with agents (win work & provide assessors) Insurers and Insurance Brokers Centralised analysis

20 // 20 FDA CLEARED, CE MARK, TGA SUPPORTED BY CLINICAL TRIAL DATA INSPIRING THE WORLD TO MOVE WELL

21 // 21 US HEALTH MARKET LOOKING FOR COST SAVING Healthcare technology will reduce the burden on health systems globally by: Improving decision making & timely intervention Allowing point-of-care diagnosis and treatment Safe and clinically proven care Personalised treatment plans Patient monitoring and tracking $309B $560B $243B $188B Diabetes Cancer Heart Disease Chronic Pain

22 CLINICAL TRIAL SHOWS TREATMENT AND COST BENEFIT // 22 Clinical Treatment Benefit Economic/Cost Benefit This evaluation has identified that motion-sensor biofeedback intervention using ViMove system was both more effective and less costly overall than the control from the societal perspective. Rarely are health care interventions found to be both more effective and less costly overall Professor Terry Haines (Monash University) RANDOMISED CONTROLLED TRIAL Peer reviewed clinical trial showing dramatic improvement for low back pain 8 week program Lasting benefit at 12 months 45% pain Exceptional health economic 73% function outcomes

23 SIGNIFICANT UNTAPPED OPPORTUNITY // devices in the market 160 devices in the market 24,000 physios (0.5% penetration) 90 devices in the market 48,000 physios 130 devices in the market 284,000 physical therapists

24 CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND COMMUNICATION Insurer // 24 PATIENT REPORTS AND DATA $ Doctor Employer Patient Specialist Physio Hospital Live Assessment Live Training Monitoring Biofeedback Exercises Reports

25 // 25 CLINICAL SALES AND REVENUE MODEL Targeting large and company-owned franchise networks UK YPP USA MeyerPT Relationship with Select Medical (pilot with 20 of their 2,000 sites) Collaborative product developments Product currently commercially released: ViPerform AMI Revenue New pricing model will feature up front payment for dorsavi kit, plus an ongoing monthly subscription fee based on the number of modules selected

26 PLANNED PRODUCT RELEASES ON NEW SENSOR PLATFORM // 26 New cloud-based clinical application for: Running Knee New cloud-based clinical application for: Low Back Walking Functional Hamstring Mar 2017 May 2017

27 // 27 BRANDING AND CREDIBILITY INSPIRING THE WORLD TO MOVE WELL

28 // 28 ELITE SPORTS MARKET: WORKING WITH THE INNOVATORS Working with thought leaders Optimising algorithms to meet market needs Test market for future consumer product

29 Outlook // 29

30 // 30 PRODUCT EVOLUTION: FIRST MOVER ADVANTAGE

31 // 31 WORLD LEADERS USING dorsavi TECHNOLOGY Unique insights coming from these commercial research projects Potential for new IP and publications 45,000 individual data sets and building daily 75+ COMMERCIAL RESEARCH PROJECTS Medical device and pharmaceutical companies now using dorsavi as an outcome measure

32 // 32 MIZUNO RUNNING SOLUTION Retail pilot program in the UK with sports shoe specialist Mizuno Objective is to better match runners with the correct shoe and increase their sales revenue Confirm viability of ViMove technology in a retail environment The initial results of the pilot are very encouraging not only is the running assessment with ViMove Run impacting positively on sales in these stores, but also is engaging customers with personalised information which they value. I expect this to further drive brand loyalty. Rob Henderson, UK Marketing Manager, Mizuno Corporation UK

33 For personal use only // 33 UPCOMING NEWSFLOW Annuity revenue from OHS customers Launch of mini-sensors into the clinical and sports markets Launch of extensive platform changes and introduction of apps to clinical product New OHS contracts with major corporates (US, UK & Australia) Appointment of additional US OHS sales agents Expansion of commercial research projects

34 // 34 dorsavi Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: Mobile: dorsavi.com